Eli Lilly has announced significant price reductions for its weight loss drug, Zepbound, in an effort to enhance patient accessibility and encourage the use of its digital healthcare platform, LillyDirect. The single-dose vials will now retail for $299 per month, a decrease from the previous price of $349. Additionally, the 5-milligram dosage will be available for $399, reduced from $499, while other approved doses will be priced at $449.
Eli Lilly’s Digital Healthcare Platform
LillyDirect, which launched in early 2024, targets consumers lacking insurance or those whose insurance doesn’t adequately cover medications. It allows patients to access Zepbound and Mounjaro directly through the Zepbound Self-Pay Journey Program.
Pricing Overview
- Single-dose vials: $299 (down from $349)
- 5 mg dose: $399 (down from $499)
- Other doses: $449
- Regular prices (without the Self-Pay Journey Program):
- 7.5 mg: $599
- 10 mg: $699
- 12.5 mg: $849
- 15 mg: $1,049
This price reduction follows earlier announcements by Eli Lilly regarding lower prices for Zepbound multi-dose pens, which are still pending approval from the Food and Drug Administration (FDA). Beginning as early as April 2026, Medicare patients will be able to purchase Zepbound in multi-dose pens for no more than $50 per month, provided the necessary approvals are secured.
Competitive Landscape
In the weight loss drug market, Eli Lilly faces competition from Novo Nordisk, which produces Wegovy and Ozempic. Both companies are investing in direct-to-consumer platforms to streamline access for patients facing financial barriers. Novo Nordisk introduced its NovoCare Pharmacy platform in March to assist those who struggle to afford its weight loss medications.
Future Availability
- Zepbound multi-dose pen (lowest dose): $299
- Multi-dose refills on LillyDirect: Maximum $449
- Orforglipron (once-a-day weight loss pill): Starting at $149, with additional doses up to $399
The collaborative efforts of Eli Lilly and Novo Nordisk aim to improve the accessibility of weight loss drugs, while also positioning themselves competitively within this growing market. By reducing prices and enhancing digital health platforms, both companies are making strides in supporting patient needs in the weight loss sector.
